Fate Therapeutics FATE 深 滬
等待開盤 10-08 09:30:00 美东时间
2.15
-0.140
-6.11%
華盛通- 最 高2.30
- 今 開2.28
- 成交量 86.30万股
- 最 低 2.14
- 昨 收 2.29
- 總市值 2.58亿
- 52周最高 3.23
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 0.95
- 委 比 -18.03%
- 總股本 1.20亿
- 歷史最高 121.16
- 量 比 0.61
- 振 幅 6.99%
- 歷史最低 0.6611
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the poten...
09-25 19:07
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Fate Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 2 RECLAIM-LN trial of FT819, an off-the-shelf CAR T-cell therapy for refractory lupus nephritis (LN). LN is a severe manifestation of systemic lupus erythematosus (SLE) affecting about 150,000 patients in the U.S., with limited treatment options. FT819 aims to provide a scalable, cost-effective therapy that can be...
09-25 11:00
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-...
09-16 19:03
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs targeting autoimmune diseases will be presented at the ACR Convergence 2026 in Orlando. The presentations cover clinical updates on FT819, including outpatient administration and biomarker associations, as well as preclinical studies on FT839, a dual-CAR T-cell therapy targeting CD19 and CD38. The company emphasizes its commitment to making cell therapy acc...
09-16 11:00
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
Fate Therapeutics Inc ($FATE) announced an update on their ongoing clinical stu...
09-03 00:31
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC Development and Readin...
08-14 19:05
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated its Phase 2 RECLAIM-LN trial of FT819, an off-the-shelf CAR T-cell therapy, for patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The trial aims to enroll approximately 53 patients and assess the proportion achieving complete renal response at Week 26. FT819 is derived from induced pluripotent stem cells (iPSCs), offering a scalable, cost-effective, and readily ava...
08-14 11:00
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $2.082 millio...
08-13 20:55
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE:PXED) fell sharply in pre-market trading after the company reported third-quarter financial results and cut its FY26 sales guidance b...
07-15 20:02
